Cargando…
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario
SIMPLE SUMMARY: Immune checkpoint inhibitors currently represent the standard of care for the treatment of different tumor types and have also been proven to be effective in several disease settings. However, their use is associated with a peculiar toxicity profile, related to the enhancement of the...
Autores principales: | Spagnolo, Calogera Claudia, Giuffrida, Giuseppe, Cannavò, Salvatore, Franchina, Tindara, Silvestris, Nicola, Ruggeri, Rosaria Maddalena, Santarpia, Mariacarmela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818218/ https://www.ncbi.nlm.nih.gov/pubmed/36612243 http://dx.doi.org/10.3390/cancers15010246 |
Ejemplares similares
-
Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do
por: Zito, Concetta, et al.
Publicado: (2022) -
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023) -
Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database
por: Russo, Giulia, et al.
Publicado: (2023) -
Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine
por: Longhitano, Elisa, et al.
Publicado: (2023) -
Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023)